Three types of medical treatment for CS have been developed, including the pituitary-directed drugs, which target the pituitary tumour inhibiting the ACTH secretion (for CD), the adrenal-directed drugs, which target the adrenal and inhibit the adrenal steroidogenesis (for all CS types), and glucocorticoid receptor-directed drugs, which act at peripheral levels, blocking the activity of glucocorticoid receptors (for all CS types). The gene discussed is NR3C1; the disease is pituitary tumor.